Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | PDE4A | P27815 | 1/20 | 0.34 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5510114 | 1.00 | NR1H2 (0.46) | NR1H2MEN1ALDH1A1KMT2ATSHR | |
| SCHEMBL19098260 | 1.00 | NR1H2 (0.46) | NR1H2MEN1ALDH1A1KMT2ATSHR | |
| SCHEMBL19063793 | 1.00 | NR1H2 (0.46) | NR1H2MEN1ALDH1A1KMT2ATSHR | |
| SCHEMBL2930654 | 0.91 | NR1H2 (0.50) | NR1H2MEN1ALDH1A1KMT2ATSHR | |
| SCHEMBL2930651 | 0.91 | NR1H2 (0.50) | NR1H2MEN1ALDH1A1KMT2ATSHR | |
| SCHEMBL1052491 | 0.91 | NR1H2 (0.50) | NR1H2MEN1ALDH1A1KMT2ATSHR | |
| SCHEMBL23692789 | 0.87 | ALDH1A1 (0.46) | NR1H2MEN1ALDH1A1KMT2ATSHR | |
| SCHEMBL15720999 | 0.87 | ALDH1A1 (0.46) | NR1H2MEN1ALDH1A1KMT2ATSHR | |
| SCHEMBL7026410 | 0.87 | ALDH1A1 (0.46) | NR1H2MEN1ALDH1A1KMT2ATSHR | |
| SCHEMBL17032291 | 0.87 | ALDH1A1 (0.46) | NR1H2MEN1ALDH1A1KMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3400228-B1 | FUSED QUADRACYCLIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | TABOMEDEX BIOSCIENCES INC (US) | 2022-04-13 | — | — | EP | disclosed |
| US-10562909-B2 | Fused quadracyclic compounds, compositions and uses thereof | Tabomedex Biosciences, LLC (US) | 2020-02-18 | — | — | US | disclosed |
| US-10562909-B2 | Fused quadracyclic compounds, compositions and uses thereof | Tabomedex Biosciences, LLC (US) | 2020-02-18 | — | — | US | disclosed |
| EP-3400228-A1 | FUSED QUADRACYCLIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | Tabomedex Biosciences, LLC (US) | 2018-11-14 | — | — | EP | disclosed |
| US-20180319809-A1 | FUSED QUADRACYCLIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | Tabomedex Biosciences, LLC | 2018-11-08 | — | — | US | disclosed |
| US-10059718-B2 | Fused quadracyclic compounds, compositions and uses thereof | Tabomedex Biosciences, LLC (US) | 2018-08-28 | — | — | US | disclosed |
| WO-2017120164-A1 | FUSED QUADRACYCLIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | Tabomedex Biosciences, LLC (US) | 2017-07-13 | — | — | WO | disclosed |
| US-20170190713-A1 | FUSED QUADRACYCLIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | WUXI APPTEC (HONG KONG) CO., LIMITED (HK) | 2017-07-06 | — | — | US | disclosed |
| US-20170190713-A1 | FUSED QUADRACYCLIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | WUXI APPTEC (HONG KONG) CO., LIMITED (HK) | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180319809-A1 | FUSED QUADRACYCLIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | MKNK2, CYP2J2, PTGS2 | NR1H2 703/4885MEN1 833/4885ALDH1A1 4091/4885 |
| US-10059718-B2 | Fused quadracyclic compounds, compositions and uses thereof | MKNK2, CYP2J2, PTGS2 | NR1H2 703/4885MEN1 833/4885ALDH1A1 4091/4885 |
| US-10562909-B2 | Fused quadracyclic compounds, compositions and uses thereof | MKNK2, CYP2J2, PTGS2 | NR1H2 703/4885MEN1 833/4885ALDH1A1 4091/4885 |
| US-20170190713-A1 | FUSED QUADRACYCLIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | MKNK2, CYP2J2, PTGS2 | NR1H2 703/4885MEN1 833/4885ALDH1A1 4091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.